PDF(Pubmed)
Abstract：
Adenosquamous carcinoma of the pancreas (ASCP) is a very rare and highly aggressive variant of pancreatic ductal adenocarcinoma, accounting for 0.5-4% of all pancreatic cancer cases in the USA. Current data indicate that epigenetic changes and MYC overexpression lead to squamous transdifferentiation of pancreatic tumor cells and development of ASCP. Minnelide™, an oral anti-super-enhancer drug that inhibits MYC expression in preclinical models of ASCP, has demonstrated safety in a phase I study. We describe the design for a phase II, open-label, single-arm trial of Minnelide in patients with advanced refractory ASCP.
Adenosquamous carcinoma of the pancreas (ASCP) is a rare and highly aggressive variant of pancreatic cancer, with limited treatment options. Changes in activation of DNA elements called super-enhancers drive the growth of ASCP. Minnelide™ is an oral drug that blocks the super-enhancer network and is safe to give to patients with advanced cancer. This trial is designed to determine whether Minnelide can shrink tumors in patients with ASCP who have already received at least one previous treatment for their cancer. Clinical Trial Registration: NCT04896073 (ClinicalTrials.gov).
Adenosquamous carcinoma of the pancreas (ASCP) is a rare and highly aggressive variant of pancreatic cancer, with limited treatment options. Changes in activation of DNA elements called super-enhancers drive the growth of ASCP. Minnelide™ is an oral drug that blocks the super-enhancer network and is safe to give to patients with advanced cancer. This trial is designed to determine whether Minnelide can shrink tumors in patients with ASCP who have already received at least one previous treatment for their cancer. Clinical Trial Registration: NCT04896073 (ClinicalTrials.gov).
摘要：
胰腺腺鳞癌（ASCP）是胰腺导管腺癌的一种非常罕见且高度侵袭性的变体，占美国所有胰腺癌病例的0.5-4%。目前的数据表明，表观遗传变化和MYC过表达导致胰腺肿瘤细胞的鳞状转分化和ASCP的发展。Minnelide™,一种在ASCP临床前模型中抑制MYC表达的口服抗超增强剂药物，在一期研究中证明了安全性。我们描述了第二阶段的设计，开放标签，米纳利德在晚期难治性ASCP患者中的单臂试验。
胰腺腺鳞癌（ASCP）是胰腺癌的一种罕见且高度侵袭性的变种，有限的治疗选择。称为超级增强子的DNA元件的激活变化驱动ASCP的生长。Minnelide™是一种口服药物，可以阻断超级增强剂网络，并且可以安全地给予晚期癌症患者。该试验旨在确定Minnelide是否可以缩小ASCP患者的肿瘤，这些患者已经接受了至少一种先前的癌症治疗。临床试验注册：NCT04896073（ClinicalTrials.gov）。
胰腺腺鳞癌（ASCP）是胰腺癌的一种罕见且高度侵袭性的变种，有限的治疗选择。称为超级增强子的DNA元件的激活变化驱动ASCP的生长。Minnelide™是一种口服药物，可以阻断超级增强剂网络，并且可以安全地给予晚期癌症患者。该试验旨在确定Minnelide是否可以缩小ASCP患者的肿瘤，这些患者已经接受了至少一种先前的癌症治疗。临床试验注册：NCT04896073（ClinicalTrials.gov）。
